Analyst Rating Update on Zimmer Biomet Holdings (ZBH)

Zimmer Biomet Holdings (ZBH) : Zacks Investment Research ranks Zimmer Biomet Holdings (ZBH) as 3, which is a Hold recommendation. 13 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 3 other analysts are mildly bullish on the stock and favor a Buy. A total of 7 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 23 research analysts is 1.72, which indicates as a Buy.

Zimmer Biomet Holdings (ZBH) : The consensus price target for Zimmer Biomet Holdings (ZBH) is $136.67 for the short term with a standard deviation of $13.64. The most optimist securities analyst among the 15 who monitor the stock believes that the stock can reach $150, however, the pessimist price target for the company is $105.

For the current week, the company shares have a recommendation consensus of Buy.


Zimmer Biomet Holdings (NYSE:ZBH): The stock opened at $130.70 on Wednesday but the bulls could not build on the opening and the stock topped out at $130.79 for the day. The stock traded down to $129.97 during the day, due to lack of any buying support eventually closed down at $130.43 with a loss of -0.12% for the day. The stock had closed at $130.59 on the previous day. The total traded volume was 952,380 shares.

Zimmer Biomet Holdings, Inc., formerly Zimmer Holdings, Inc. is a musculoskeletal healthcare company. The Company designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products. The Company manages its operations through three geographic segments: the Americas, comprising principally of the United States and includes other North, Central and South American markets; Europe, comprising principally of Europe and includes the Middle East and African markets; and Asia Pacific, comprising primarily of Japan and includes other Asian and Pacific markets. The Company markets and sells products through three channels: direct to healthcare institutions, such as hospitals or direct channel accounts; through stocking distributors and healthcare dealers, and directly to dental practices and dental laboratories.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.